Abstract
The nicotinic α7 agonist dimethoxybenzilidene anabaseine (DMXB) and cholinesterase inhibitor tetrahydroaminoacridine (THA) were investigated in a trans-synaptic model for neocortical atrophy and degeneration following nucleus basalis lesions. Bilateral lesions reduced parietal neuronal density in layers II–V 8 months later. DMXB administered i.p. daily to rats for 3 months attenuated this loss in layers II–V at a 1 mg/kg i.p. dose. A lower, 0.2 mg/kg i.p. dose, was neuroprotective in layer IV only. THA (1 mg/kg i.p.) also protected against neocortical Nissl-staining deficits.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
